Incidence of AIDS-Related Kaposi Sarcoma in All 50 United States From 2000 to 2014.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 08 2019
01 08 2019
Historique:
entrez:
27
6
2019
pubmed:
27
6
2019
medline:
25
2
2020
Statut:
ppublish
Résumé
Although declining rates of incident AIDS-related Kaposi sarcoma (KS) have been reported, KS incidence rates have noted race/ethnic, age, and geographic diversity. We performed a comprehensive assessment of recent secular trends in AIDS-related KS incidence in the United States. We identified incident KS diagnosed in men aged 20-54 years (who comprise most AIDS-related KS in the United States) using the US Cancer Statistics registry data. Joinpoint analysis assessed for trends in age-adjusted incidence rates between 2000 and 2014 calculating average annual percentage changes (AAPCs) with 95% confidence intervals. Heat maps were generated to compare age-adjusted HIV incidence rates with KS incidence rates. Age-adjusted KS incidence rates nationwide decreased from 1.44/100,000 to 0.95/100,000 between 2000 and 2014. Observed rate changes varied across subgroups; eg, there were significant decreases in 30-44 years (AAPC = -5.4%), particularly in Whites and Blacks, significant increases among 20-29 years (AAPC = 2.7), primarily in Blacks, and stable rates among 45-54 years (AAPC = -0.03). In Southern United States, the incidence rates among Blacks did not significantly change. The states with highest average age-adjusted rates over the study period were Georgia (2.71/100,000), New York (2.16/100,000), California (2.02/100,000), Florida (1.90/100,000), and Texas (1.39/100,000), with significantly decreasing trends over time, except Georgia where rates increased (AAPC = 1.8). Although KS incidence rates have decreased nationally, age, racial, and geographic disparities persist, including increasing risk among younger Black men and particularly elevated rates in some southern states and urban areas. Further research is needed to address racial and geographic AIDS-related KS disparities.
Sections du résumé
BACKGROUND
Although declining rates of incident AIDS-related Kaposi sarcoma (KS) have been reported, KS incidence rates have noted race/ethnic, age, and geographic diversity. We performed a comprehensive assessment of recent secular trends in AIDS-related KS incidence in the United States.
METHODS
We identified incident KS diagnosed in men aged 20-54 years (who comprise most AIDS-related KS in the United States) using the US Cancer Statistics registry data. Joinpoint analysis assessed for trends in age-adjusted incidence rates between 2000 and 2014 calculating average annual percentage changes (AAPCs) with 95% confidence intervals. Heat maps were generated to compare age-adjusted HIV incidence rates with KS incidence rates.
RESULTS
Age-adjusted KS incidence rates nationwide decreased from 1.44/100,000 to 0.95/100,000 between 2000 and 2014. Observed rate changes varied across subgroups; eg, there were significant decreases in 30-44 years (AAPC = -5.4%), particularly in Whites and Blacks, significant increases among 20-29 years (AAPC = 2.7), primarily in Blacks, and stable rates among 45-54 years (AAPC = -0.03). In Southern United States, the incidence rates among Blacks did not significantly change. The states with highest average age-adjusted rates over the study period were Georgia (2.71/100,000), New York (2.16/100,000), California (2.02/100,000), Florida (1.90/100,000), and Texas (1.39/100,000), with significantly decreasing trends over time, except Georgia where rates increased (AAPC = 1.8).
CONCLUSIONS
Although KS incidence rates have decreased nationally, age, racial, and geographic disparities persist, including increasing risk among younger Black men and particularly elevated rates in some southern states and urban areas. Further research is needed to address racial and geographic AIDS-related KS disparities.
Identifiants
pubmed: 31242141
doi: 10.1097/QAI.0000000000002050
pii: 00126334-201908010-00004
pmc: PMC9400914
mid: NIHMS1524351
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
387-394Subventions
Organisme : NIAID NIH HHS
ID : P30 AI027767
Pays : United States
Organisme : BLRD VA
ID : I01 BX000507
Pays : United States
Organisme : CSRD VA
ID : I01 CX000174
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA174647
Pays : United States
Organisme : CSRD VA
ID : I01 CX001430
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206476
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA022453
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA172880
Pays : United States
Organisme : NIA NIH HHS
ID : R03 AG040583
Pays : United States
Références
Stat Med. 2000 Feb 15;19(3):335-51
pubmed: 10649300
JAMA. 2011 Apr 13;305(14):1450-9
pubmed: 21486978
Lancet. 1990 Jan 20;335(8682):123-8
pubmed: 1967430
AIDS. 2016 Jun 19;30(10):1663-8
pubmed: 26950314
PLoS One. 2017 Aug 22;12(8):e0182750
pubmed: 28829790
Mod Pathol. 2008 May;21(5):572-82
pubmed: 18376387
Int J Cancer. 2008 Jul 1;123(1):187-94
pubmed: 18435450
Oncology (Williston Park). 1996 Jun;10(6 Suppl):9-12; discussion 37-8
pubmed: 16871704
Stat Methods Med Res. 2006 Dec;15(6):547-69
pubmed: 17260923
Clin Infect Dis. 2018 Jun 18;67(1):50-57
pubmed: 29325033
Br J Cancer. 2005 Jan 17;92(1):188-93
pubmed: 15570306
J Natl Cancer Inst. 2016 Dec 31;109(5):
pubmed: 28040691
AIDS. 2014 Mar 27;28(6):881-90
pubmed: 24300545
Epidemiol Infect. 2013 Jan;141(1):200-6
pubmed: 22404880
Cancer Lett. 2011 Jun 28;305(2):150-62
pubmed: 21377267
Am J Prev Med. 2006 Feb;30(2 Suppl):S25-36
pubmed: 16458787
Cancer. 2014 Jul 15;120(14):2191-8
pubmed: 24866103